Urinary miRNA in Endometrial Cancer Study

Urinary microRNA Expression in Endometrial Cancer Patients - a Feasibility Study

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03824613

Enrollment

164

Registered

2019-01-31

Start date

2019-03-08

Completion date

2020-03-26

Last updated

2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial Cancer

Brief summary

This study is a prospective feasibility study with the addition of a retrospective cohort study on the the expression of microRNA in urine in endometrial cancer patients.

Interventions

DIAGNOSTIC_TESTUrinary miRNA

MiRNA detection in urine

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

FEMALE

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* Confirmed diagnosis of endometrial cancer * Age: 18 years or older

Exclusion criteria

* Prior or coexisting other malignancies * Autoimmune disorders (other than diabetes mellitus)

Design outcomes

Primary

Measure	Time frame	Description
Accuracy of predictive value of miRNA test in detecting endometrial cancer	6 months	To determine if miRNA can distinguish endometrial cancer patients from healthy patients

Secondary

Measure	Time frame	Description
Correlation to final histology	6 months	To determine how well miRNA correlates with final histology, i.e. can miRNA determine the subtype of endometrial cancer

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026